Mono Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Meningococcal Vaccine, Japanese Encephalitis Vaccine, Yellow Fever Vaccine, Hepatitis Vaccine & Cholera Vaccine), By Application (Adults & Children) and Regional Insights and Forecast to 2032

• 

  Request a Free sample to learn more about this report

MONO VACCINE MARKET REPORT OVERVIEW

The global Mono Vaccine Market size was USD 14.25 billion in 2023 and will touch USD 23.98 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period.

The monovalent vaccine is an extra-ordinary immunisation that is aimed at offering a form of protection that is specific to one pathogen, which can be a strain of a certain virus or bacterium. The strategy of confining the action to a single agent is based on the fact that the vaccine should produce a well-proportioned and selective immune response that will improve the body’s ability to recognise a specific pathogen if it enters the body again.

COVID-19 IMPACT

Market Growth Restrained due to Disrupted Production and Distribution

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic entailed the various negative impacts on the market for vaccines; the supply chain of vaccines, together with their production and distribution, were severely disrupted. It forced an overwhelming demand across the international market, which then impacted manufacturing abilities and contributed to shortages of core resources.

LATEST TRENDS

Advancements in Genomics and Biotechnology to Propel the Market Growth

Other developments witnessed in the vaccine market in the recent past are focused vaccine development and advancements in genomics and biotechnology in the development of onsite vaccines that are targeted at specific genetic groups and precise strains of pathogens. The techniques involving mRNA, which acted well in COVID-19 vaccines, are now being undertaken in other viral diseases and, interestingly, cancer. Another emerging trend refers to the multiple, intertrain, and heterologous protection afforded by vaccines and the advances in vaccination delivery systems and networks with global health institutions. 

Request a Free sample to learn more about this report

MONO VACCINE MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Meningococcal Vaccine, Japanese Encephalitis Vaccine, Yellow Fever Vaccine, Hepatitis Vaccine & Cholera Vaccine

• Meningococcal Vaccine: They work against the meningococcal disease that is brought on by Neisseria meningitidis. They comprise several serogroup vaccines (A, B, C, W135, and Y). Usual for young people, volunteers, students, and persons who are newly enlisted in the military service or are going to travel.

• Japanese Encephalitis Vaccine: Prevents infection with the Japanese encephalitis virus that is transmitted through the bite of mosquitoes. The common preparations are inactivated or live-attenuated. Considering for travellers to an area that is considered the hot spot for transmission of the virus and for some occupational categories.

• Yellow Fever Vaccine: Offers protection against the yellow fever virus that is spread through the bite of a mosquito. This, anti-Vish, is predominantly a live-attenuated vaccine. Essential for people visiting epidemic countries and other types of international certifications.

• Hepatitis Vaccine: Averts hepatitis ‘A’, ‘B’, and ‘A & B’ viruses. FDA-approved vaccines are for hepatitis A, B, and the combined vaccines like Hep A and Hep B. Given to infants, high-risk clients, and those travelling to new places.

• Cholera Vaccine: Can help reduce the infection with cholera-agent Vibrio cholerae. Oral vaccines of inactivated and live-attenuated types are part of this category. Aim is at travellers intending to visit or undertaking missions in cholera-endemic zones and during outbreaks.

By Application

Based on application the market can be categorized into Adults & Children

• Adults: Immunisations for illnesses in adults range from tropical immunisations (for trips to areas of specific diseases such as yellow fever or Japanese encephalitis) to immunisations that anyone of any age should be receiving (like meningococcal immunisation or hepatitis immunisation, etc.). One is for people in special groups who work in risky occupations, for instance, health care providers or even servicemen.

• Children: Immunisations routinely provided to children for the prevention of common illnesses (i.e., hepatitis B, meningococcal). Mainly provided to children who are visiting a particular area or country with specific diseases, for example, yellow fever and Japanese encephalitis, among others.

DRIVING FACTORS

Increased Global Travel and Migration to Expand the Market

One of the key driving factors of Mono Vaccine Market growth is Increased Global Travel and Migration. Investments are necessary to address new and resurgent diseases from abroad, which have increased travel and immigration, such as yellow fever, Japanese encephalitis, and cholera, among others that need vaccines.

Growing Awareness and Prevention Initiatives to Advance the Market

A growing number of cases of dangerous infectious diseases and the recognition of the significance of vaccination as a means of combating them contributed to the expansion of the vaccine market.

RESTRAINING FACTOR

High Development and Production Costs to Pose Potential Impediments on this Market

The high costs involved in the production of vaccines range from the discovery of the vaccine to clinical trials, manufacture, and distribution, which hinder the immunisation programs, research and development of vaccines, and vaccines’ prices. 

• Request a Free sample to learn more about this report

•  

MONO VACCINE MARKET REGIONAL INSIGHTS

North America to Dominate the Market due to its Well-Developed Infrastructure

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

North America has emerged as the most dominant region in the Mono Vaccine Market share because of the well-developed infrastructure in this region, along with stronger encouraging policies in the fields of health research and vaccination programs. The region has well-developed pharmaceutical industries and many biotech firms that are innovating in products and production. The governments of the region and related organisations provide immense budgets and sponsorships to implement vaccine programs. Overall, it places North America as one of the crucial players in the global vaccine market.

KEY INDUSTRY PLAYERS

Key Players Transforming the Mono Vaccine Market through Developments 

Larger organisations, including those in the industrial sector, have a great impact on the vaccine market since their research leads to the development of better and improved vaccines. They have immense investments that enable them to have extensive production houses and produce vaccines in sufficient amounts so that they don’t run out. Moreover, such companies influence market developments through the consolidation of synergistic mutual ventures, mergers, and acquisitions; their marketing and distribution channels create demographic reach for vaccine distribution, contributing to world health and varying market factors.

List of  Top Mono Vaccine Companies

• GSK (U.K.)
• Sanofi Pasteur (France)
• Merck (Germany)
• Pfizer (U.S.)
• CNBG (China)

INDUSTRIAL DEVELOPMENT

August 2024: Merck aimed to strengthen its positions in the sphere of the biopharmaceutical industry by acquiring. This transaction took place in August 2024 and has the main purpose of expanding the range of viral vector bioprocessing services at Merck. In this sense, including Mirus Bio’s knowledge, Merck aims to improve its competencies in the sphere of the elaboration and production of progressive innovative therapies, including gene and cell therapies. This strategic move places Merck as a major player in the fledgling area of viral vector-based treatments.

REPORT COVERAGE

This report is based on historical analysis and forecast calculation that aims to help readers get a comprehensive understanding of the global Mono Vaccine Market from multiple angles, which also provides sufficient support to readers’ strategy and decision-making. Also, this study comprises a comprehensive analysis of SWOT and provides insights for future developments within the market. It examines varied factors that contribute to the growth of the market by discovering the dynamic categories and potential areas of innovation whose applications may influence its trajectory in the upcoming years. This analysis encompasses both recent trends and historical turning points into consideration, providing a holistic understanding of the market’s competitors and identifying capable areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.